BioCentury | Oct 19, 2019
Product Development

How GSK has rebuilt its oncology pipeline from the ground up

Less than two years into GSK's cancer rebuild, Hal Barron is making measurable strides to reposition the pharma as an immunology-focused company. His turnaround boasts an expanded immuno-oncology pipeline, replete with multiple modalities, and two...
BC Week In Review | Mar 29, 2019
Clinical News

GSK planning BLA for dostarlimab in endometrial cancer

GSK plans to submit a BLA to FDA at the end of the year for dostarlimab (formerly TSR-042) to treat endometrial cancer after reporting that the humanized anti-PD-1 mAb as monotherapy led to an overall...
BC Week In Review | Feb 8, 2019
Company News

Via Merck KGaA Deal, GSK adds to growing immuno-oncology pipeline

Two months after announcing it would pay $5.1 billion for Tesaro Inc., GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) has partnered with Merck KGaA (Xetra:MRK) in another deal to bolster its immuno-oncology pipeline. GSK is paying the German...
BC Extra | Feb 5, 2019
Company News

Via Merck KGaA deal, GSK adds to growing immuno-oncology pipeline

Two months after announcing it would pay $5.1 billion for Tesaro Inc., GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) has partnered with Merck KGaA (Xetra:MRK) in another deal to bolster its immuno-oncology pipeline. GSK is paying the German...
BioCentury | Dec 7, 2018
Finance

Taking Tesaro

While the $5.1 billion takeout price for Tesaro Inc. (NASDAQ:TSRO) is a far cry from its $9.8 billion peak valuation, investors who spoke with BioCentury see the final price tag as a fair value. GlaxoSmithKline...
BC Week In Review | Dec 7, 2018
Company News

GSK gains Zejula, immuno-oncology portfolio in $5.1B Tesaro takeout

Although it's inheriting a portfolio of cancer compounds from Tesaro Inc. (NASDAQ:TSRO) that fall squarely into competitive areas, GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) expects to transform the candidates, including Zejula niraparib, into best-in-class therapies under Hal...
BC Extra | Dec 4, 2018
Company News

GSK gains Zejula, immuno-oncology pipeline in $5.1B Tesaro acquisition

Although it's inheriting a portfolio of cancer compounds from Tesaro Inc. (NASDAQ:TSRO) that fall squarely into competitive areas, GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) expects to transform the candidates, including Zejula niraparib, into best-in-class therapies under Hal...
BC Extra | Nov 17, 2018
Company News

Tesaro stock rebounds on takeout report

Tesaro Inc. (NASDAQ:TSRO) declined to comment on a report of a potential sale that drove the company's stock up $8.37 (31%) to $34.96 on Friday. Tesaro has engaged advisers to explore a sale after receiving...
BC Week In Review | Nov 16, 2018
Clinical News

Tesaro combo leads to partial responses in NSCLC patients

Tesaro Inc. (NASDAQ:TSRO) reported data from the open-label Phase I AMBER trial showing that a combination of TSR-022 and TSR-042 led to four confirmed partial responses and 11 cases of stable disease among 31 evaluable...
BC Extra | Nov 10, 2018
Clinical News

Investors ding Tesaro despite responses for combo in NSCLC

Tesaro Inc. (NASDAQ:TSRO) reported data Friday from the Phase I AMBER trial showing that a combination of TSR-022 and TSR-042 led to four confirmed partial responses and 11 cases of stable disease among 31 evaluable...
Items per page:
1 - 10 of 16